A Randomized, Double-Blind, Placebo-Controlled Dose Ranging Study Evaluating Safety, Pharmacokinetics and Clinical Benefit of FLU-IGIV in Hospitalized Patients With Serious Influenza A Infection
Phase of Trial: Phase II
Latest Information Update: 17 Jul 2019
Price : $35 *
At a glance
- Drugs Influenza-immune-globulin-Emergent-BioSolutions (Primary)
- Indications Influenza A virus infections
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Emergent BioSolutions
- 15 Jul 2019 Status changed from recruiting to completed.
- 12 Apr 2019 Planned End Date changed from 30 Jun 2019 to 3 Jul 2019.
- 12 Apr 2019 Planned primary completion date changed from 30 Jun 2019 to 3 Jul 2019.